The FDA has approved Enbumyst offering a self-administered outpatient option for managing edema in patients with heart failure, liver disease, and kidney disease.
Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates